Steph & Co. Has $440,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Steph & Co. lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 23.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,578 shares of the biopharmaceutical company’s stock after selling 2,571 shares during the period. Steph & Co.’s holdings in Bristol-Myers Squibb were worth $440,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in BMY. True Wealth Design LLC acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at about $26,000. Coppell Advisory Solutions Corp. acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $31,000. Coppell Advisory Solutions LLC bought a new stake in Bristol-Myers Squibb in the 2nd quarter valued at $28,000. Live Oak Investment Partners acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth $33,000. Finally, OFI Invest Asset Management bought a new stake in Bristol-Myers Squibb in the 3rd quarter valued at about $25,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BMY. Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Wells Fargo & Company dropped their price target on Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 6th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. Finally, Bank of America downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $68.00 to $60.00 in a research report on Wednesday, January 3rd. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $61.12.

Bristol-Myers Squibb Trading Down 0.9 %

NYSE BMY traded down $0.42 on Wednesday, hitting $47.84. The company’s stock had a trading volume of 11,723,377 shares, compared to its average volume of 15,847,039. The firm has a market cap of $96.96 billion, a PE ratio of 12.50, a PEG ratio of 1.46 and a beta of 0.39. The company’s 50-day moving average is $51.27 and its 200 day moving average is $51.62. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. Bristol-Myers Squibb has a 1-year low of $47.58 and a 1-year high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The business had revenue of $11.48 billion during the quarter, compared to analyst estimates of $11.19 billion. During the same period last year, the company earned $1.82 EPS. Bristol-Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, analysts predict that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 5.02%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is presently 62.18%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.